The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
FGF-21 as a novel metabolic regulator
Open accessAbstract
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, FGF21 stimulates the uptake of glucose by adipocytes and inhibits the production of glucose in the liver.”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FGF21 acts in the control of glucose and lipid homeostasis (Kharitonenkov et al., 2005).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, FGF21 appears to protect pancreatic β cells from cell death induced by glycotoxicity (Kharitonenkov et al., 2005, 2007).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, mice that overexpress FGF-21, a circulating FGF which is induced by a ketogenic diet 106, are lean and have increased brown fat 107, suggesting that the beneficial metabolic effects induced by a ketogenic diet are brought about in part by increases in BAT mass.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [107]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“overexpression of FGF21 is highly protective [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“activation of the FGF21/FGFR1c/KLB receptor complex results in the phosphorylation of ERK1/2 and FRS2α [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In rodents, pharmacological levels of FGF21 increase energy expenditure (64, 141), which results in increased food intake (54, 64).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In addition, FGF21 enhances insulin sensitivity in primary brown adipocytes (86) but not in primary white adipocytes (64, 86).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [114]
In the citing paper
“Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine 61 and has been shown to be necessary for the adaptation to fasting 62, 63.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
SIGNALLING BY RECEPTOR TYROSINE KINASES
Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.453 · Cited by 1,118
Cheatham, B., Vlahos, C. J., Cheatham, L. A., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902-4911.1994 · Cited by 1,062
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Research works printed but not linked: 3
- Konishi, 1999, J. Biol. Chem., 255, 12119
- Shah, 2000, J. Clin. Endocrinol. Metab., 85, 4053
- Cheatham, 1994, Mol. Cell. Biol., 14, 4902, 10.1128/MCB.14.7.4902 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,008
A single combination gene therapy treats multiple age-related diseases
Davidsohn, N., Pezone, M. J., Vernet, A., Graveline, A. R., Oliver, D., Slomovic, S., Punthambaker, S., Sun, X., Liao, R., Bonventre, J. V., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910073116 · Cited by 103
The FGF21–adiponectin axis in controlling energy and vascular homeostasis
Hui, X. H., Feng, T., Liu, Q., Gao, Y., & Xu, A. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw013 · Cited by 103
Raza-Iqbal, S., Tanaka, T., Anai, M., Inagaki, T., Matsumura, Y., Ikeda, K., Taguchi, A., Gonzalez, F. J., Sakai, J., & Kodama, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.28720 · Cited by 100
Frayling, T. M., Beaumont, R. N., Jones, S. E., Yaghootkar, H., Tuke, M. A., Ruth, K. S., Casanova, F., West, B., Locke, J., Sharp, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.070 · Cited by 101
Taniguchi, H., Tanisawa, K., Sun, X., Kubo, T., & Higuchi, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3308 · Cited by 104
Lee, J. H., Kang, Y. E., Chang, J. Y., Park, K. C., Kim, H.-W., Kim, J. T., Kim, H. J., Yi, H., Shong, M., Chung, H. K., et al. (2016) · PubMed Central · Cited by 101
Peripherally derived FGF21 promotes remyelination in the central nervous system
Kuroda, M., Muramatsu, R., Maedera, N., Koyama, Y., Hamaguchi, M., Fujimura, H., Yoshida, M., Konishi, M., Itoh, N., Mochizuki, H., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94337 · Cited by 101
Li, Y., Wong, K., Walsh, K. X., Gao, B., & Zang, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.429852 · Cited by 101
Dong, J. Q., Rossulek, M. I., Somayaji, V. R., Baltrukonis, D. J., Liang, Y., Hudson, K. J., Hernandez‐Illas, M., & Calle, R. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12676 · Cited by 100
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 103
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. D. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 97
Yie, J., Wang, W., Deng, L., Tam, L., Stevens, J., Chen, M. M., Li, Y., Xu, J., Lindberg, R., Hecht, R., et al. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01325.x · Cited by 99
FGF21 and the physiological regulation of macronutrient preference
Hill, C. M., Qualls-Creekmore, E., Berthoud, H.-R., Soto, P., Yu, S., McDougal, D. H., Münzberg, H., & Morrison, C. D. (2020) · Endocrinology · doi:10.1210/endocr/bqaa019 · Cited by 99
Uebanso, T., Taketani, Y., Yamamoto, H., Amo, K., Ominami, H., Arai, H., Takei, Y., Masuda, M., Tanimura, A., Harada, N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022976 · Cited by 99
Hill, C. M., Laeger, T., Albarado, D. C., McDougal, D. H., Berthoud, H.-R., Münzberg, H., & Morrison, C. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-07498-w · Cited by 97
Activation of mTORC1 in skeletal muscle regulates whole-body metabolism through FGF21
Guridi, M., Tintignac, L. A. J., Lin, S., Kupr, B., Castets, P., & Rüegg, M. A. (2015) · Science Signaling · doi:10.1126/scisignal.aab3715 · Cited by 98
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Sánchez, J., Palou, A., & Picó, C. (2009) · Endocrinology · doi:10.1210/en.2009-0466 · Cited by 98
Conversion of a Paracrine Fibroblast Growth Factor into an Endocrine Fibroblast Growth Factor
Goetz, R. M., Ohnishi, M., Kır, S., Kurosu, H., Wang, L., Pastor, J. V., Ma, J., Gai, W., Kuro‐o, M., Razzaque, M. S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.342980 · Cited by 100
Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases
Kharitonenkov, A., & Shanafelt, A. B. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00004 · Cited by 98
Kim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97
Kim, E., Lee, S., Jhun, J. Y., Byun, J. K., Jeong, J. H., Lee, S.-Y., Kim, J. K., Choi, J. Y., & Cho, M. (2016) · Mediators of Inflammation · doi:10.1155/2016/5813030 · Cited by 101
Kitada, M., Ogura, Y., Suzuki, T., Sen, S., Lee, S. M., Kanasaki, K., Kume, S., & Koya, D. (2016) · Diabetologia · doi:10.1007/s00125-016-3925-4 · Cited by 97
Metabolic Determinants of Weight Gain in Humans
Piaggi, P. (2019) · Obesity · doi:10.1002/oby.22456 · Cited by 100
RECENT RESEARCH ON THE GROWTH PLATE: Recent insights into the regulation of the growth plate
Lui, J. C. K., Nilsson, O., & Baron, J. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0022 · Cited by 97
Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle
Vandanmagsar, B., Warfel, J. D., Wicks, S. E., Ghosh, S., Salbaum, J. M., Burk, D., Dubuisson, O. S., Mendoza, T. M., Zhang, J., Noland, R. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.057 · Cited by 92
Xu, P., Zhang, Y., Liu, Y., Yuan, Q., Song, L., Liu, M., Liu, Z., Yang, Y., Li, J., Li, D., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.11.012 · Cited by 97
Yan, H., Xia, M., Chang, X., Xu, Q., Bian, H., Zeng, M., Rao, S., Yao, X., Tu, Y., Jia, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024895 · Cited by 95
Wang, C., Tan, Z., Niu, B., Tsang, K. Y., Tai, A. C. P., Chan, W. C. W., Lo, R. L. K., Leung, K. K. H., Dung, N. W. F., Itoh, N., et al. (2018) · eLife · doi:10.7554/elife.37673 · Cited by 86
Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 97
Giannini, C., Feldstein, A. E., Santoro, N., Kim, G. J., Kursawe, R., Pierpont, B. M., & Caprio, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1250 · Cited by 95
Ji, K., Zheng, J., Lv, J., Xu, J., Ji, X., Luo, Y., Li, W. S., Zhao, Y., & Yan, C. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.03.020 · Cited by 95
Sun, H. D., Malabunga, M., Tonra, J. R., DiRenzo, R., Carrick, F. E., Zheng, H., Berthoud, H., McGuinness, O. P., Shen, J., Böhlen, P., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00089.2006 · Cited by 95
Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure
Ameka, M., Markan, K. R., Morgan, D. A., BonDurant, L. D., Idiga, S. O., Naber, M. C., Zhu, Z., Zingman, L. V., Grobe, J. L., Rahmouni, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37198-y · Cited by 93
Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver
Cicione, C., Degirolamo, C., & Moschetta, A. (2012) · Hepatology · doi:10.1002/hep.25929 · Cited by 95
Wu, S., Levenson, A. E., Kharitonenkov, A., & Luca, F. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.343707 · Cited by 94
MiT/TFE Family of Transcription Factors: An Evolutionary Perspective
Spina, M. L., Contreras, P. S., Rissone, A., Meena, N. K., Jeong, E., & Martina, J. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.609683 · Cited by 92
Intestinal Amino Acid Transport and Metabolic Health
Bröer, S. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-094344 · Cited by 105
Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)
Jha, P., Knopf, A., Köfeler, H. C., Mueller, M., Lackner, C., Höefler, G., Claudel, T., & Trauner, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.012 · Cited by 99
FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway
Zhu, S., Ma, L., Wu, Y., Ye, X., Zhang, T., Zhang, Q., Rasoul, L. M., Liu, Y., Guo, M., Zhou, B. R., et al. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu097 · Cited by 93
Jiang, Y. Z., Rose, A. J., Sijmonsma, T., Bröer, A., Pfenninger, A., Herzig, S., Schmoll, D., & Bröer, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.02.003 · Cited by 96
Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet
Zhang, Y.-K. J., Wu, K. C., Liu, J., & Klaassen, C. D. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.09.014 · Cited by 93
Ong, K. L., Januszewski, A. S., O'Connell, R. L., Jenkins, A. J., Xu, A., SULLIVAN, D. R., Barter, P. J., Hung, W.-T., Scott, R. S., Taskinen, M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3458-7 · Cited by 93
Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis
Domouzoglou, E. M., & Maratos–Flier, E. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001941 · Cited by 93
The Structural Biology of the FGF19 Subfamily
Beenken, A., & Mohammadi, M. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-0887-1_1 · Cited by 93
FGF21 in obesity and cancer: New insights
Lu, W., Li, X., & Luo, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.026 · Cited by 93
Kang, S., Choi, M. J., Jung, S.-B., Chung, H. K., Chang, J. Y., Kim, J. T., Kang, Y. E., Lee, J. H., Hong, H. J., Jun, S. M., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102181 · Cited by 91
FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov, A., & Shanafelt, A. B. (2009) · PubMed · Cited by 91
Arafat, A. M., Kaczmarek, P., Skrzypski, M., Pruszyńska‐Oszmałek, E., Kolodziejski, P. A., Szczepankiewicz, D., Sassek, M., Wojciechowicz, T., Wiedenmann, B. J., Pfeiffer, A. F. H., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2803-y · Cited by 90
Fibroblast Growth Factor-21 May Mediate Growth Hormone Resistance in Anorexia Nervosa
Fazeli, P. K., Misra, M., Goldstein, M. A., Miller, K. K., & Klibanski, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1730 · Cited by 90
Plasma FGF21 Is Elevated by the Intense Lipid Mobilization of Lactation
Schoenberg, K. M., Giesy, S. L., Harvatine, K. J., Waldron, M. R., Cheng, C., Kharitonenkov, A., & Boisclair, Y. R. (2011) · Endocrinology · doi:10.1210/en.2011-1425 · Cited by 90
Hypothalamic-Pituitary Axis Regulates Hydrogen Sulfide Production
Hine, C., Kim, H.-J., Zhu, Y., Harputlugil, E., Longchamp, A., Matos, M. S., Ramadoss, P., Bauerle, K. T., Brace, L. E., Asara, J. M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.003 · Cited by 89
Regulation of metabolic health by essential dietary amino acids
Green, C. L., & Lamming, D. W. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.07.004 · Cited by 91
Bhattacharya, A., Sun, S., Wang, H., Liu, M. R., Long, Q., Yin, L., Kersten, S., Zhang, K., & Qi, L. (2018) · The EMBO Journal · doi:10.15252/embj.201899277 · Cited by 88
The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology
Li, B., Cai, S., & Boyer, J. L. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166085 · Cited by 92
Grothe, C., & Timmer, M. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.12.001 · Cited by 89
Fibroblast growth factors, old kids on the new block
Li, X., Wang, C., Xiao, J., McKeehan, W. L., & Wang, F. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.12.014 · Cited by 93
Singhal, G., Kumar, G., Chan, S., Fisher, F. M., Ma, Y., Vardeh, H. G., Nasser, I. A., Flier, J. S., & Maratos-Flier, E. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.002 · Cited by 87
Targher, G., Marchesini, G., & Byrne, C. D. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.04.002 · Cited by 90
Luo, Y., Yang, Y., Liu, M., Wang, D., Wang, F., Bi, Y., Ji, J., Li, S., Liu, Y., Chen, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.030 · Cited by 87
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 88
Systemic effects of mitochondrial stress
Bar‐Ziv, R., Bolas, T., & Dillin, A. G. (2020) · EMBO Reports · doi:10.15252/embr.202050094 · Cited by 86
Wanders, D., Burk, D. H., Cortez, C. C., Van, N. T., Stone, K. P., Baker, M., Mendoza, T. M., Mynatt, R. L., & Gettys, T. W. (2015) · The FASEB Journal · doi:10.1096/fj.14-270348 · Cited by 88
Kim, S. ‐., Hu, Y., Cadman, S., & Bouloux, P. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2007.01627.x · Cited by 87
C-terminal Tail of FGF19 Determines Its Specificity toward Klotho Co-receptors
Wu, X., Lemon, B. D., Li, X., Gupte, J., Weiszmann, J., Stevens, J. L., Hawkins, N., Shen, W. D., Lindberg, R. A., Chen, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803319200 · Cited by 86
FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia
Manoli, I., Sysol, J. R., Epping, M. W., Li, L., Wang, C., Sloan, J. L., Pass, A. R., Gagné, J., Ktena, Y. P., Li, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.124351 · Cited by 87
Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D’Alessio, D. A., Campbell, J. E., & Chilkoti, A. (2020) · Science Advances · doi:10.1126/sciadv.aaz9890 · Cited by 85
Yuan, X.-M., Tsujimoto, K., Hashimoto, K., Kawahori, K., Hanzawa, N., Hamaguchi, M., Seki, T., Nawa, M., Ehara, T., Kitamura, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03038-w · Cited by 77
Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
So, W. Y., & Leung, P. S. (2016) · Medicinal Research Reviews · doi:10.1002/med.21390 · Cited by 85
Murata, Y., Konishi, M., & Itoh, N. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/981315 · Cited by 87
Dostálová, I., Haluzíková, D., & Haluzı́k, M. (2009) · Physiological Research · doi:10.33549/physiolres.931610 · Cited by 83
Keipert, S., Kutschke, M., Lamp, D., Brachthäuser, L., Neff, F., Meyer, C. W., Oelkrug, R., Kharitonenkov, A., & Jastroch, M. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.006 · Cited by 85
FGF 21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation
Yan, X., Chen, J., Zhang, C., Zhou, S., Zhang, Z., Chen, J., Feng, W., Li, X., & Tan, Y. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12530 · Cited by 85
Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesity
Li, Y., Mouche, S., Sajic, T., Veyrat‐Durebex, C., Supale, R., Pierroz, D. D., Ferrari, S., Negro, F., Hasler, U., Féraille, E., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.279 · Cited by 84
Lee, Y., Lim, S. K., Hong, E. S., Kim, J. H., Moon, M. K., Chun, E. J., Choi, S. I., Kim, Y., Park, Y. J., Park, K. S., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12134 · Cited by 84
Wang, H., Xiao, Y., Fu, L., Zhao, H., Zhang, Y., Wan, X., Qin, Y., Huang, Y., Gao, H., & Li, X. (2010) · BMC Biotechnology · doi:10.1186/1472-6750-10-14 · Cited by 84
Klotho Coreceptors Inhibit Signaling by Paracrine Fibroblast Growth Factor 8 Subfamily Ligands
Goetz, R. M., Ohnishi, M., Ding, X., Kurosu, H., Wang, L., Akiyoshi, J., Ma, J., Gai, W., Sidis, Y., Pitteloud, N., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06603-11 · Cited by 86
Diabetes mellitus: new challenges and innovative therapies
Sena, C. M., Bento, C. F., Pereira, P., & Seiça, R. M. F. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 92
Molecular and Environmental Mechanisms Regulating Puberty Initiation: An Integrated Approach
Livadas, S., & Chrousos, G. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00828 · Cited by 84
Renal senescence in 2008: progress and challenges
Zhou, X. J., Saxena, R., Liu, Z., Vaziri, N. D., & Silva, F. G. (2008) · International Urology and Nephrology · doi:10.1007/s11255-008-9405-0 · Cited by 83
Ong, K. L., Rye, K., O'Connell, R. L., Jenkins, A. J., Brown, C. S. B., Xu, A., SULLIVAN, D. R., Barter, P. J., KEECH, A. C., & on behalf of the FIELD study investigators (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2267 · Cited by 82
Chou, R., Huang, P., Hsu, C., Chang, C. C., Leu, H., Huang, C., Chen, J., & Lin, S. (2016) · Scientific Reports · doi:10.1038/srep33953 · Cited by 82
The Role of the Gut Microbiome in Energy Balance With a Focus on the Gut-Adipose Tissue Axis
Han, X., & Kang, S. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00297 · Cited by 88
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 82
The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders
Porcuna, J., Mínguez-Martínez, J., & Ricote, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910573 · Cited by 82
mTORC1 is Required for Brown Adipose Tissue Recruitment and Metabolic Adaptation to Cold
Labbé, S. M., Mouchiroud, M., Caron, A., Secco, B., Freinkman, E., Lamoureux, G., Gélinas, Y., Lecomte, R., Bossé, Y., Chimin, P., et al. (2016) · Scientific Reports · doi:10.1038/srep37223 · Cited by 82
Lu, P., Yan, J., Liu, K., Garbacz, W. G., Wang, P., Xu, M., Ma, X., & Xie, W. (2015) · Hepatology · doi:10.1002/hep.27719 · Cited by 80
Circulating FGF21 Levels in Human Health and Metabolic Disease
Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 83
Mitochondrial uncoupling and longevity – A role for mitokines?
Klaus, S., & Ost, M. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110796 · Cited by 80
Role of Fibroblast Growth Factor 21 (FGF21) in Undernutrition-Related Attenuation of Growth in Mice
Kubicky, R. A., Wu, S., Kharitonenkov, A., & Luca, F. D. (2012) · Endocrinology · doi:10.1210/en.2011-1909 · Cited by 84
Central Resistin/TLR4 Impairs Adiponectin Signaling, Contributing to Insulin and FGF21 Resistance
Benomar, Y., Amine, H., Crépin, D., Al Rifai, S., Riffault, L., Gertler, A., & Taouis, M. (2016) · Diabetes · doi:10.2337/db15-1029 · Cited by 76
Kuro‐o, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0887-1_2 · Cited by 80
Cyphert, H. A., Alonge, K. M., Ippagunta, S. M., & Hillgartner, F. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094996 · Cited by 80
Stein, S., Stepan, H., Kratzsch, J., Verlohren, M., Verlohren, H.-J., Drynda, K., Lössner, U., Blüher, M., Stümvoll, M., & Faßhauer, M. (2009) · Metabolism · doi:10.1016/j.metabol.2009.07.003 · Cited by 81
Kuro-o, M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy126 · Cited by 80
Obesity as the common soil of non‐alcoholic fatty liver disease and diabetes: Role of adipokines
Hui, E., Xu, A., Yang, H. B., & Lam, K. S. L. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12093 · Cited by 79
Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression
Feng, S., Dakhova, O., Creighton, C., & Ittmann, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4108 · Cited by 79
Kim, W., Park, K. J., Hwang, J., Kim, G. H., Lee, D.-Y., Lee, Y. J., Song, E. H., Yoo, M., Kim, B.-J., Suh, Y. H., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.023 · Cited by 79
Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction
Hindricks, J., Ebert, T., Bachmann, A., Kralisch, S., Lössner, U., Kratzsch, J., Stolzenburg, J., Dietel, A., Beige, J., Anders, M. S., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12380 · Cited by 80
Lee, M. S., Choi, S., Ha, E. S., An, S.-Y., Kim, T. H., Han, S. J., Kim, H. J., Kim, D. J., KANG, Y. Y., & Lee, K. W. (2012) · Metabolism · doi:10.1016/j.metabol.2012.01.012 · Cited by 80
Metadata
- Authors
- Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D.-S., Mehrbod, F., Jaskunas, S. R., & Shanafelt, A. B.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1627-1635
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1088017
- OpenAlex
- W2000665430
- Cited by
- 2,125
- References
- 46
- Citations by year
- 2026: 72 · 2025: 99 · 2024: 111 · 2023: 120 · 2022: 137 · 2021: 138 · 2020: 116 · 2019: 136 · 2018: 147 · 2017: 135 · 2016: 142 · 2015: 155 · 2014: 124 · 2013: 125 · 2012: 115
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Hospital for Sick Children
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, diabetes mellitus, glucose uptake, adipocytes, diet-induced obesity, transgenic mice, ob/ob mice, db/db mice, plasma glucose, triglycerides, metabolic regulation, diabetes treatment
- MeSH terms
- Animals, Blood Glucose, Cell Division, Cells, Cultured, Diabetes Mellitus, Fibroblast Growth Factors, Humans, Hyperglycemia, Hypoglycemic Agents, Mice, Obese, Mice, Transgenic, Triglycerides, Weight Gain, Adipocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
